Abstract
Background: Paradoxical psoriasis occurs in pediatric patients following treatment with biologic agents. These presentations are not well described, and optimal treatment strategies have not been established.Objective: To describe the reported rates, demographic characteristics, clinical presentation, and treatment options for TNF‐α inhibitor–induced psoriasis.Methods: Systematic review of published cases and cohort studies of paradoxical psoriasis induced by biologic agents, with specific reference to TNF‐α inhibitors.Results: We identified 4564 pediatric patients treated with TNF‐α inhibitors, of whom 210 (4.6%) developed paradoxical psoriasis. Infliximab was the drug most likely to induce psoriasis (8.3%), followed by adalimumab (3.3%). Individual‐level data were acquired from 129 individuals with a mean age of 13.6 years (SD: 4.0); 45.0% were male. The scalp was the most commonly affected area (47.5%), followed by the ears (30.8%). Most (63.3%) patients were continued on TNF‐α inhibitor therapy. Among those who switched TNF‐α inhibitors, only 32.0% had complete clearance of their skin lesions. Among patients who were switched to a non‐TNF‐α inhibitor, 81% had complete clearance of their paradoxical psoriasis.Limitations: Data were acquired from retrospective studies including case reports and case series.Conclusion: TNF‐α inhibitor–induced psoriasis is a common adverse effect; however, most patients can continue their original therapy and be managed with skin‐directed topical or systemic medications. If a patient requires medication discontinuation, switching to a new TNF‐α inhibitor is unlikely to lead to resolution of their skin lesions.

This publication has 25 references indexed in Scilit: